Literature DB >> 20057988

[Testosterone replacement therapy for prostate cancer].

A Kaminsky1, H Sperling.   

Abstract

During the male 40s total testosterone levels decrease continuously. If clinical symptoms like decreasing libido, erectile dysfunction, osteoporosis, altered distribution of body fat, reduction in physical strength, or alterations in psychological mood are combined with a decreased serum testosterone level late-onset hypogonadism (LOH) is obvious. Before the substitution of testosterone is initiated, it is essential to exclude prostate cancer because the progress of prostate cancer depends on androgens. The question is now how to treat patients who suffer from androgen deficiency but have cured prostate cancer in their history? Concerning this there are only a few studies with a small number of patients which show that testosterone substitution therapy is possible without an increased risk for recurrence of prostate cancer. As long as the patient was cured it does not matter if he underwent a radical prostatectomy or brachytherapy. Absolutely necessary is that the patient is well informed about the therapy and regularly controlled during the therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20057988     DOI: 10.1007/s00120-009-2194-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  15 in total

Review 1.  [Diagnosis of the "aging male"--what is recommended?].

Authors:  V S Lenk
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

2.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.

Authors:  Jason C Massengill; Leon Sun; Judd W Moul; Hongyu Wu; David G McLeod; Christopher Amling; Raymond Lance; John Foley; Wade Sexton; Leo Kusuda; Andrew Chung; Douglas Soderdahl; Timothy Donahue
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

4.  Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy.

Authors:  K C Tan; S W Shiu; A W Kung
Journal:  Clin Endocrinol (Oxf)       Date:  1999-12       Impact factor: 3.478

5.  Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.

Authors:  Michael F Sarosdy
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

Review 6.  [PADAM from the urologic viewpoint].

Authors:  G Ludwig
Journal:  Urologe A       Date:  2000-09       Impact factor: 0.639

Review 7.  Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

Authors:  Joel M Kaufman; R James Graydon
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

Review 8.  [Testosterone and the prostate].

Authors:  H Sperling; R Rossi; G Lümmen; H Rübben
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

Review 9.  Testosterone therapy in men with prostate cancer: scientific and ethical considerations.

Authors:  Abraham Morgentaler
Journal:  J Urol       Date:  2009-01-16       Impact factor: 7.450

10.  Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Authors:  Robert M Coward; Jay Simhan; Culley C Carson
Journal:  BJU Int       Date:  2008-12-23       Impact factor: 5.588

View more
  2 in total

Review 1.  [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].

Authors:  P Thelen; R-H Ringert; H Loertzer; A Strauß
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 2.  [Testosterone substitution therapy in prostate cancer].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2011-08       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.